Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.

MedStar author(s):
Citation: Journal of Clinical Oncology. 41(21):3712-3723, 2023 07 20.PMID: 37192435Institution: MedStar Washington Hospital CenterDepartment: Internal Medicine ResidencyForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Carcinoma, Hepatocellular | *Carcinoma, Non-Small-Cell Lung | *Head and Neck Neoplasms | *HIV Infections | *Liver Neoplasms | *Lung Neoplasms | Carcinoma, Non-Small-Cell Lung/dt [Drug Therapy] | Female | HIV Infections/dt [Drug Therapy] | Humans | Immune Checkpoint Inhibitors/ae [Adverse Effects] | Lung Neoplasms/dt [Drug Therapy] | Male | Middle Aged | Retrospective Studies | Squamous Cell Carcinoma of Head and Neck | Year: 2023Local holdings: Available online from MWHC library: 1999 - present, Available in print through MWHC library: 1999 - 2008ISSN:
  • 0732-183X
Name of journal: Journal of clinical oncology : official journal of the American Society of Clinical OncologyAbstract: CONCLUSION: Among PWH, ICIs demonstrated differential activity across cancer types with no excess toxicity. Safety and activity of ICIs were similar between matched cohorts of PWH and PWOH with mNSCLC.METHODS: This retrospective study included PWH treated with anti-PD-1- or anti-PD-L1-based therapies for advanced cancers. Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Objective response rates (ORRs) were measured per RECIST 1.1 or other tumor-specific criteria, whenever feasible. Restricted mean survival time (RMST) was used to compare OS and PFS between matched PWH and PWOH with metastatic NSCLC (mNSCLC).PURPOSE: Compared with people living without HIV (PWOH), people living with HIV (PWH) and cancer have traditionally been excluded from immune checkpoint inhibitor (ICI) trials. Furthermore, there is a paucity of real-world data on the use of ICIs in PWH and cancer.RESULTS: Among 390 PWH, median age was 58 years, 85% (n = 331) were males, 36% (n = 138) were Black; 70% (n = 274) received anti-PD-1/anti-PD-L1 monotherapy. Most common cancers were NSCLC (28%, n = 111), hepatocellular carcinoma ([HCC]; 11%, n = 44), and head and neck squamous cell carcinoma (HNSCC; 10%, n = 39). Seventy percent (152/216) had CD4+ T cell counts >=200 cells/microL, and 94% (179/190) had HIV viral load <400 copies/mL. Twenty percent (79/390) had any grade immune-related adverse events (irAEs) and 7.7% (30/390) had grade >=3 irAEs. ORRs were 69% (nonmelanoma skin cancer), 31% (NSCLC), 16% (HCC), and 11% (HNSCC). In the matched mNSCLC cohort (61 PWH v 110 PWOH), 20% (12/61) PWH and 22% (24/110) PWOH had irAEs. Adjusted 42-month RMST difference was -0.06 months (95% CI, -5.49 to 5.37; P = .98) for PFS and 2.23 months (95% CI, -4.02 to 8.48; P = .48) for OS.All authors: Abdallah W, Abdel-Wahab N, Aboubakar Nana F, Abu Ghazal B, Addeo A, Adib E, Al-Hader A, Arora A, Baden LR, Baena J, Bahary N, Baiocchi RA, Bakalov V, Bankapur A, Barletta G, Bersanelli M, Bower M, Chiao EY, Choueiri TK, Cortellini A, Dalla Pria A, Diab A, Dima D, Dittus C, Dizman N, Dobbs RW, Drakaki A, Drolen C, El Zarif T, El-Am E, Emu B, Falohun A, Fitzgerald BG, Florou V, Freeman D, Funchain P, Genova C, Hall E, Haykal T, Huang J, Idossa D, Johnson DB, Kim C, Kozaily E, Lamberti G, Lechner MG, Li M, Long GV, Lopetegui-Lia N, Lorentsen M, Lurain K, Mangla A, Marron TU, McKay RR, Menzies AM, Mittra A, Morse MA, Mouhieddine TH, Naqash AR, Nassar AH, Nebhan CA, Nonato T, Owen DH, Pinato DJ, Puri S, Queirolo P, Rajkumar A, Ramaswami R, Reed A, Reid EG, Rubinstein PG, Saeed A, Saleem R, Saponara M, Shah NJ, Shah V, Sharon E, Singh P, Sonpavde GP, Woodford R, Xie WOriginally published: Original year of publication: 2023Fiscal year: Fiscal year of original publication: FY2023Digital Object Identifier:
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 37192435 Available 37192435

Available online from MWHC library: 1999 - present, Available in print through MWHC library: 1999 - 2008

CONCLUSION: Among PWH, ICIs demonstrated differential activity across cancer types with no excess toxicity. Safety and activity of ICIs were similar between matched cohorts of PWH and PWOH with mNSCLC.

METHODS: This retrospective study included PWH treated with anti-PD-1- or anti-PD-L1-based therapies for advanced cancers. Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Objective response rates (ORRs) were measured per RECIST 1.1 or other tumor-specific criteria, whenever feasible. Restricted mean survival time (RMST) was used to compare OS and PFS between matched PWH and PWOH with metastatic NSCLC (mNSCLC).

PURPOSE: Compared with people living without HIV (PWOH), people living with HIV (PWH) and cancer have traditionally been excluded from immune checkpoint inhibitor (ICI) trials. Furthermore, there is a paucity of real-world data on the use of ICIs in PWH and cancer.

RESULTS: Among 390 PWH, median age was 58 years, 85% (n = 331) were males, 36% (n = 138) were Black; 70% (n = 274) received anti-PD-1/anti-PD-L1 monotherapy. Most common cancers were NSCLC (28%, n = 111), hepatocellular carcinoma ([HCC]; 11%, n = 44), and head and neck squamous cell carcinoma (HNSCC; 10%, n = 39). Seventy percent (152/216) had CD4+ T cell counts >=200 cells/microL, and 94% (179/190) had HIV viral load <400 copies/mL. Twenty percent (79/390) had any grade immune-related adverse events (irAEs) and 7.7% (30/390) had grade >=3 irAEs. ORRs were 69% (nonmelanoma skin cancer), 31% (NSCLC), 16% (HCC), and 11% (HNSCC). In the matched mNSCLC cohort (61 PWH v 110 PWOH), 20% (12/61) PWH and 22% (24/110) PWOH had irAEs. Adjusted 42-month RMST difference was -0.06 months (95% CI, -5.49 to 5.37; P = .98) for PFS and 2.23 months (95% CI, -4.02 to 8.48; P = .48) for OS.

English

Powered by Koha